January 12, 2021
|
Leading Ophthalmology Organization Launches Podcast Video with Firas Rahhal, MD, to Explore the Genesis and Promise of Outlook Therapeutics’ ONS-5010/LYTENAVA™ (bevacizumab-vikg)
|
|
January 5, 2021
|
Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
|
|
December 23, 2020
|
Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update
|
|
December 1, 2020
|
Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
|
November 19, 2020
|
Outlook Therapeutics Announces Creation of Global Retina Advisory Council
|
|
November 11, 2020
|
Virtual KOL Roundtable Recap: Outlook Therapeutics and Firas Rahhal, MD, Discussed wet AMD Treatment Landscape and ONS-5010/LYTENAVA™
|
|
November 5, 2020
|
Outlook Therapeutics Secures $10 Million in Additional Working Capital
|
|
November 3, 2020
|
Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
|
|
October 22, 2020
|
Outlook Therapeutics to Present at the Virtual Investor KOL Roundtable
|
|
October 13, 2020
|
Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
|
|